Ultragenyx (NASDAQ:RARE) — Market Cap & Net Worth
Market Cap & Net Worth: Ultragenyx (RARE)
Ultragenyx (NASDAQ:RARE) has a market capitalization of $1.98 Billion ($1.98 Billion) as of May 2, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #6308 globally and #1882 in its home market, demonstrating a 2.02% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Ultragenyx's stock price $24.77 by its total outstanding shares 96477569 (96.48 Million). Analyse Ultragenyx cash conversion from operations to see how efficiently the company converts income to cash.
Ultragenyx Market Cap History: 2015 to 2026
Ultragenyx's market capitalization history from 2015 to 2026. Data shows change from $10.82 Billion to $2.39 Billion (-11.42% CAGR).
Index Memberships
Ultragenyx is a constituent of 4 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Dow Jones Biotechnology
DJUSBT
|
$1.09 Trillion | 0.18% | #19 of 39 |
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.08% | #152 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.01% | #680 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.67 Trillion | 0.12% | #97 of 263 |
Weight: Ultragenyx's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Ultragenyx Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Ultragenyx's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
3.30x
Ultragenyx's market cap is 3.30 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $6.78 Billion | $133.00K | -$245.87 Million | 51002.54x | N/A |
| 2017 | $4.47 Billion | $2.61 Million | -$302.14 Million | 1713.10x | N/A |
| 2018 | $4.19 Billion | $51.49 Million | -$197.61 Million | 81.46x | N/A |
| 2019 | $4.12 Billion | $103.71 Million | -$402.73 Million | 39.73x | N/A |
| 2020 | $13.36 Billion | $271.03 Million | -$186.57 Million | 49.28x | N/A |
| 2021 | $8.11 Billion | $351.41 Million | -$454.02 Million | 23.09x | N/A |
| 2022 | $4.47 Billion | $363.33 Million | -$707.42 Million | 12.30x | N/A |
| 2023 | $4.61 Billion | $434.25 Million | -$606.64 Million | 10.62x | N/A |
| 2024 | $4.06 Billion | $560.23 Million | -$569.18 Million | 7.24x | N/A |
| 2025 | $2.22 Billion | $673.00 Million | -$575.00 Million | 3.30x | N/A |
Competitor Companies of RARE by Market Capitalization
Companies near Ultragenyx in the global market cap rankings as of May 2, 2026.
Key companies related to Ultragenyx by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Ultragenyx Historical Marketcap From 2015 to 2026
Between 2015 and today, Ultragenyx's market cap moved from $10.82 Billion to $ 2.39 Billion, with a yearly change of -11.42%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $2.39 Billion | +7.70% |
| 2025 | $2.22 Billion | -45.33% |
| 2024 | $4.06 Billion | -12.02% |
| 2023 | $4.61 Billion | +3.22% |
| 2022 | $4.47 Billion | -44.90% |
| 2021 | $8.11 Billion | -39.25% |
| 2020 | $13.36 Billion | +224.12% |
| 2019 | $4.12 Billion | -1.77% |
| 2018 | $4.19 Billion | -6.25% |
| 2017 | $4.47 Billion | -34.03% |
| 2016 | $6.78 Billion | -37.32% |
| 2015 | $10.82 Billion | -- |
End of Day Market Cap According to Different Sources
On May 2nd, 2026 the market cap of Ultragenyx was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.98 Billion USD |
| MoneyControl | $1.98 Billion USD |
| MarketWatch | $1.98 Billion USD |
| marketcap.company | $1.98 Billion USD |
| Reuters | $1.98 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Ultragenyx
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth fac… Read more